be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Reach out to potential partners and customers in the Danish-Swedish life science cluster, Medicon Valley
Central European Healthcare Expo (20-21.05.2020 Global Expo Warsaw)
The world of healthcare ...

All articles

Filters:

Show search box

2013-11-12

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Merck, one of the leaders in production of pharmaceuticals, put its new medicine under review. It is called vintafolide, MK-8109 and it is an injectable drug conjugate consisting of folate (vitamin B9) linked to alkaloid chemotherapy agent, desacetylvinblastine monohydrazine (DAVLBH). ... Read more

Tags medicine , cancer , Merck , MSD , cancer targetting